Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06988150 · ClinicalTrials.gov registry record

Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)

A clinical trial of Weight Loss and Pancreatic Adenocarcinoma, sponsored by Cedars-Sinai Medical Center.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT06988150 is a study of Weight Loss and Pancreatic Adenocarcinoma that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 100 participants, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06988150, a study of Weight Loss and Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with diagnosed pancreatic adenocarcinoma and clinically diagnosed weight loss will be enrolled in this study.

Study Locations (1)

California

  • Cedars-Sinai Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-04-14
Est. Completion 2026-04-14

Sponsor

Cedars-Sinai Medical Center

339 total trials

What the Registry Record Tells You About NCT06988150

The ClinicalTrials.gov registry entry for NCT06988150 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (93% lower). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Weight Loss appearing as the primary indexed condition, and to 0 interventions.

NCT06988150 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06988150 about?

NCT06988150 is a clinical study titled "Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)". The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with...

What is the current status of trial NCT06988150?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-04-14. Estimated completion is 2026-04-14.

What conditions does trial NCT06988150 study?

This clinical trial studies the following conditions: Weight Loss, Pancreatic Adenocarcinoma.

Who is sponsoring clinical trial NCT06988150?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06988150 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Weight Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.